Related references
Note: Only part of the references are listed.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2022 Recommendations of the International Antiviral Society-USA Panel
Rajesh T. Gandhi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study
Myroslava Nikolaichuk et al.
HIV MEDICINE (2023)
Viral hepatitis in persons living with HIV in the post-COVID era
Vicente Soriano et al.
AIDS REVIEWS (2023)
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
Jose-Manuel Ramos-Rincon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)
Susceptibility to hepatitis B virus infection in adults living in Spain
Vicente Soriano et al.
LIVER INTERNATIONAL (2023)
Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2023)
Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis
Hsuan-Yu Hung et al.
ANNALS OF MEDICINE (2022)
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu et al.
GUT (2022)
Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
Vicente Soriano et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021
Lene Ryom et al.
HIV MEDICINE (2022)
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
Jose-Manuel Ramos-Rincon et al.
JOURNAL OF VIRAL HEPATITIS (2022)
Real-life experience of hepatitis C treatment in a Spanish prison
Rosa Juana Tejera-Perez et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2022)
Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases
Vicente Soriano et al.
FUTURE MICROBIOLOGY (2022)
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
Chen-Hua Liu et al.
HEPATOLOGY INTERNATIONAL (2022)
An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression
Srijanee Das et al.
SCIENCE ADVANCES (2022)
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project
Claudio Borghi et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Lenacapavir: First Approval
Julia Paik
DRUGS (2022)
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution
Francesco Pes et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)
Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Brittney S. Sheena et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
Sabela Lens et al.
JHEP REPORTS (2022)
Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018
Laurent Cotte et al.
CLINICAL INFECTIOUS DISEASES (2021)
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
Gail V. Matthews et al.
JOURNAL OF HEPATOLOGY (2021)
The Changing Liver Transplant Recipient From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol
Ross Vyhmeister et al.
CLINICS IN LIVER DISEASE (2021)
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
Chen-Hua Liu et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Hepatitis C: A Pharmacological Therapeutic Update
Sonia Santander Ballestin et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naive Hepatitis C Virus Infection
Tasuku Hara et al.
INTERNAL MEDICINE (2021)
Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach
Edward R. Cachay et al.
JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE (2021)
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach
Mathieu Castry et al.
GUT (2021)
Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals
Matthew P. Kosloski et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Marianne Martinello et al.
HEPATOLOGY (2020)
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
Robert C. Bollinger et al.
LANCET HIV (2020)
A year-long extended release nanoformulated cabotegravir prodrug
Tanmay A. Kulkarni et al.
NATURE MATERIALS (2020)
EASL recommendations on treatment of hepatitis C: Final update of the series
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2020)
Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
Edward R. Cachay et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M. Borgia et al.
JOURNAL OF HEPATOLOGY (2019)
Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe
H. Stoever et al.
BMC PUBLIC HEALTH (2019)
Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection
C-H Liu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers
Erik Mogalian et al.
CLINICAL INFECTIOUS DISEASES (2018)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Juergen K. Rockstroh et al.
CLINICAL INFECTIOUS DISEASES (2018)
Should we treat acute hepatitis C? A decision and cost-effectiveness analysis
Emily D. Bethea et al.
HEPATOLOGY (2018)
Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population
Cameron Sikavi et al.
HEPATOLOGY (2018)
Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
Tomoko Tadokoro et al.
INTERNAL MEDICINE (2018)
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries
Rob Bielen et al.
HARM REDUCTION JOURNAL (2018)
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis
Marcus M. Muecke et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice
J. Macias et al.
HIV MEDICINE (2017)
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
Nat Wright et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C
Vicente Soriano et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Drug interactions in HIV-infected patients treated for hepatitis C
Vicente Soriano et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Paul Kwo et al.
GASTROENTEROLOGY (2017)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil
Yuanjun Shen et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
Cheng Wang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care
Harjot K. Singh et al.
CLINICAL INFECTIOUS DISEASES (2017)
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
David Wyles et al.
CLINICAL INFECTIOUS DISEASES (2017)
Hepatitis C cure with antiviral therapy - benefits beyond the liver
Vincent Soriano et al.
ANTIVIRAL THERAPY (2016)
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir
Erik Mogalian et al.
CLINICAL PHARMACOKINETICS (2016)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial
Gregory J. Dore et al.
ANNALS OF INTERNAL MEDICINE (2016)
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
C. S. Voican et al.
ANNALS OF ONCOLOGY (2016)
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge
Anne De Monte et al.
JOURNAL OF CLINICAL VIROLOGY (2016)
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
Aude Desnoyer et al.
JOURNAL OF HEPATOLOGY (2016)
Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
Lucy Platt et al.
LANCET INFECTIOUS DISEASES (2016)
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
Huilian Wang et al.
MEDICINE (2016)
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection
Kristen L. Bunnell et al.
PHARMACOTHERAPY (2016)
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
Marianne Martinello et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Treatment Considerations for Unique Patient Populations With HCV Genotype I Infection
Kimberly A. Toussaint-Miller et al.
ANNALS OF PHARMACOTHERAPY (2015)
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C
Yousef Fazel et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era?
Norah Terrault
HEPATOLOGY (2015)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Saleh A. Alqahtani et al.
HEPATOLOGY (2015)
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Tariq Ahmad et al.
HEPATOLOGY (2015)
Treatment of hepatitis C in difficult-to-treat patients
Peter Ferenci
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Emerging Challenges in Managing Hepatitis B in HIV Patients
Vincent Soriano et al.
CURRENT HIV/AIDS REPORTS (2015)
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
R. S. Koff
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients A Cohort Study
Vincent Lo Re et al.
ANNALS OF INTERNAL MEDICINE (2014)
Towards hepatitis C eradication from the HIV-infected population
Pablo Barreiro et al.
ANTIVIRAL RESEARCH (2014)
Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies
Pablo Labarga et al.
ANTIVIRAL THERAPY (2014)
Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
Drosos E. Karageorgopoulos et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
Reducing Barriers to Hepatitis C Treatment among Drug Users: An Integrated Hepatitis C Peer Education and Support Program
Robert J. Roose et al.
JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED (2014)
Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management
Jose V. Fernandez-Montero et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan
Chun-Ju Chiang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions
David Burger et al.
JOURNAL OF HEPATOLOGY (2013)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain
Clara Sanchez et al.
LIVER INTERNATIONAL (2013)
VIRAL HEPATITIS Treating hepatitis C in injection drug users
Vincent Soriano et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Drug-drug interactions during antiviral therapy for chronic hepatitis C
Jennifer J. Kiser et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration
Charlotte Lewden et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
Mei-Hsuan Lee et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients
Inmaculada Jimenez-Nacher et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany-A Case-Control Study
Axel J. Schmidt et al.
PLOS ONE (2011)
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
Pablo Labarga et al.
AIDS (2009)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Hepatitis c virus activation in HIV-infected patients initiating highly active antiretroviral therapy
H. Nina Kim et al.
AIDS PATIENT CARE AND STDS (2007)
Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: Lopinavir-ritonavir versus nelfinavir
KE Sherman et al.
CLINICAL INFECTIOUS DISEASES (2005)
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense
EM Leslie et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)
Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution
L Martín-Carbonero et al.
AIDS (2002)